Related Experiment Video
Updated: Jul 10, 2026
07:48
Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia
Published on: June 8, 2019
Therapeutic myocardial angiogenesis
Marie-Ange Renault1, Douglas W Losordo
1Feinberg Cardiovascular Research Institute, Northwestern University Feinberg School of Medicine, 303 E Chicago Ave., Tarry 12-703, Chicago, IL 60611, USA.
Microvascular Research
|October 24, 2007
Summary
Scientists are exploring angiogenesis to treat vascular diseases. This approach may help patients with end-stage coronary artery disease (CAD) by regenerating blood vessels.
Area of Science:
- Cardiovascular Medicine
- Regenerative Medicine
- Biomedical Engineering
Background:
- Angiogenesis, the formation of new blood vessels, is crucial for treating ischemic syndromes.
- Patients with end-stage coronary artery disease (CAD) often lack treatment options due to ineligibility for mechanical revascularization.
- Chronic myocardial ischemia in these patients presents a significant unmet medical need.
Purpose of the Study:
- To investigate the therapeutic potential of harnessing angiogenesis for treating peripheral vascular and coronary ischemic syndromes.
- To explore regenerative strategies for patients with end-stage CAD and chronic myocardial ischemia.
Main Methods:
- Reviewing the current understanding of angiogenesis mediators.
- Assessing the applicability of angiogenic therapies in clinical settings.
- Evaluating the potential for microvasculature regeneration in ischemic conditions.
Main Results:
- Improved understanding of angiogenesis mediators facilitates therapeutic interventions.
- Angiogenesis offers a promising avenue for patients unsuitable for traditional revascularization.
- Regeneration of depleted microvasculature is a key target for treating chronic myocardial ischemia.
Conclusions:
- Targeting angiogenesis represents a significant advancement in treating vascular and ischemic diseases.
- Regenerative approaches hold promise for patients with end-stage CAD.
- Further research into harnessing angiogenesis can improve outcomes for patients with chronic myocardial ischemia.
Related Concept Videos
01:10Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...